Generic Animal Drug Advancement Act

HR 1683, the Generic Animal Drug Advancement Act, simplifies the approval process for generic animal drugs by changing bioequivalence requirements. It requires manufacturers to demonstrate that a generic drug is bioequivalent to an approved drug in *at least one major species* (not all species), making it easier to bring generic versions to market. This directly affects animal drug manufacturers seeking to produce lower-cost alternatives to existing approved drugs. The bill clarifies key terms like "bioequivalent" and "patent" within the existing regulatory framework to streamline approvals.